Skip to main content
. 2021 Dec 31;10(4):213–219. doi: 10.1055/s-0041-1742080

Fig. 3.

Fig. 3

Consensus flowchart for treatment of HR+ Her2-patients who are eligible for prognostic tests, based on the survey of 185 oncologists in India.